Clinical Trials
16
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
VIDAS® TBI Real Life Performance in Subjects with Mild Traumatic Brain Injury (mTBI)
- Conditions
- Mild Traumatic Brain Injury
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- BioMérieux
- Target Recruit Count
- 900
- Registration Number
- NCT06449183
- Locations
- 🇺🇸
Orlando Health, Orlando, Florida, United States
🇺🇸Wayne State University, Detroit, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
- Conditions
- DengueMalariaChikungunya
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- BioMérieux
- Target Recruit Count
- 804
- Registration Number
- NCT06257810
- Locations
- 🇧🇫
Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso
🇨🇮CHU Cocody, Abidjan, Cocody, Côte D'Ivoire
🇨🇮CHU Treichville, Abidjan, Treichville, Côte D'Ivoire
LUNG INFECTION in ICU (LUNG-I3)
- Conditions
- VAP - Ventilator Associated Pneumonia
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- BioMérieux
- Target Recruit Count
- 68
- Registration Number
- NCT06073834
- Locations
- 🇫🇷
Hopital Edouard Herriot, Lyon, France
VIDAS® NEPHROCLEAR Diagnostic Accuracy Study
- Conditions
- Acute Kidney InjuryStage 2 Acute Kidney InjuryStage 3 Acute Kidney Injury
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- BioMérieux
- Target Recruit Count
- 477
- Registration Number
- NCT06036758
- Locations
- 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
VIDAS® NEPHROCLEAR Reference Interval Study
- Conditions
- Healthy
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- BioMérieux
- Target Recruit Count
- 585
- Registration Number
- NCT06037109
- Locations
- 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸University of Illinois Chicago, Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- Next
News
FDA Clears bioMérieux's VITEK COMPACT PRO System to Combat Antimicrobial Resistance
bioMérieux has received FDA 510(k) clearance for its VITEK COMPACT PRO system, designed to improve microorganism identification and antibiotic susceptibility testing in clinical and industrial laboratories.
bioMérieux's BIOFIRE Tropical Fever Panel Receives FDA Clearance for Rapid Pathogen Identification
bioMérieux's BIOFIRE FILMARRAY Tropical Fever Panel has received FDA 510(k) clearance, enabling rapid identification of pathogens causing tropical fevers.
UK Government Partners with Oxford Nanopore to Launch NHS-Wide Pathogen Surveillance System
Oxford Nanopore and the UK Government have formed a strategic partnership to implement a real-time pathogen surveillance system across 30 NHS sites, aiming to strengthen national biosecurity.